Forbes October 9, 2024
Despite the boom in popularity of expensive GLP-1 drugs to treat weight loss, fewer than one in five large employers are covering such prescriptions, a new KFF analysis shows.
And even those employers that do cover these drugs, which include Wegovy, Rybelsus, Saxenda, Zepbound and Ozempic, such coverage comes with conditions.
GLP-1 drugs, or Glucagon-like peptide-1 agonists, are used to help control blood sugar levels in people with type-2 diabetes and have also been shown to effectively help people lose weight. They are often used off label for weight loss.
But the high price of these drugs, which can cost $700 to $1,400 a month before any insurance or rebates kick in, has raised issues among employers and health insurance...
Today's Sponsors
Today's Sponsor